Multifactorial diagnostic model combining SAT-PCA3 in prostate cancer.

Area of Science:

• Urology
• Oncology
• Biomarker Research

Background:

• Prostate cancer (PCa) diagnosis relies on various clinical factors.
• Novel biomarkers are needed to enhance diagnostic accuracy.
• Simultaneous Amplification and Testing PCA3 (SAT-PCA3) is a promising urine-based biomarker.

Purpose of the Study:

• To evaluate the feasibility of using SAT-PCA3 combined with clinical information for PCa diagnosis.
• To compare the diagnostic performance of a combined model versus individual parameters.

Main Methods:

• Retrospective analysis of 137 patients with complete clinical data.
• Development of a multivariate diagnostic model incorporating age, DRE, PSA, PIRADS score, and SAT-PCA3.
• Comparison of diagnostic accuracy using receiver operating characteristic (ROC) curves and area under the curve (AUC).

Main Results:

• The multivariate model combining SAT-PCA3 and clinical data achieved an AUC of 0.912.
• Individual parameters showed lower AUCs: SAT-PCA3 (0.786) and PIRADS score (0.795).
• The combined model demonstrated statistically significant improvement in diagnostic accuracy (p < 0.001).

Conclusions:

• A diagnostic model integrating SAT-PCA3 with conventional clinical information significantly enhances prostate cancer diagnostic accuracy.
• This combined approach outperforms any single diagnostic parameter alone.
• The findings support the utility of SAT-PCA3 as a valuable tool in PCa detection.